Skip to main content

Pigmentary Dispersion Syndrome

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Sensimed
SensimedSwitzerland - Etagnières
1 program
SENSIMED TriggerfishN/A
Orasis Pharmaceuticals
Orasis PharmaceuticalsIsrael - Herzliya
1 program
SENSIMED TriggerfishN/A1 trial
Active Trials
NCT01253109Terminated15Est. Nov 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Orasis PharmaceuticalsSENSIMED Triggerfish

Clinical Trials (1)

Total enrollment: 15 patients across 1 trials

Continuous Intraocular Pressure (IOP) Monitoring in Pigmentary Dispersion Syndrome and Pigmentary Glaucoma Patients

Start: Sep 2010Est. completion: Nov 201115 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.